The Trump administration launched a Medicare GLP-1 Bridge program that sets the monthly cost of three weight-loss drugs—Wegovy, tirzepatide (KwikPen Zepbound), and orforglipron (Foundayo)—at $50 for eligible older adults. The initiative aims to widen access for adults age 60 and up, but clinicians warned that trial evidence in this age segment remains limited. The reporting notes that older adults are often underrepresented in early GLP-1 studies, with only about one in ten participants in early trials being age 65 or older. Experts emphasized that eligibility does not automatically translate to benefit, citing heterogeneity in comorbidity burden and side-effect sensitivity among patients in their 70s and beyond. For biotech and healthcare stakeholders, the program increases near-term exposure to GLP-1s in an aging population while sharpening demand for age-specific safety and effectiveness evidence to guide prescribing and coverage decisions.